Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
Sarcoma|October 10, 2018
Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and FranceDaniel S Mytelka, Saurabh P Nagar, Yulia D'yachkova, et al.Journal of Comparative Effectiveness Research|June 29, 2026
Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapyMurali Janakiram, Sabyasachi Ghosh, Victoria Alegria, et al.Current Medical Research and Opinion|May 8, 2019
Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancerRavi K Goyal, Gebra Cuyun Carter, Saurabh P Nagar, et al.Expert Review of Pharmacoeconomics & Outcomes Research|August 7, 2020
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United StatesRavi K Goyal, Gebra Cuyun Carter, Saurabh P Nagar, et al.Journal of Gastrointestinal Oncology|August 9, 2019
Medical record review of transition to lanreotide following octreotide for neuroendocrine tumorsMuhammad Wasif Saif, Rohan Parikh, David Ray, et al.Oncology and Therapy|April 18, 2026
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US DatabasesSurbhi Sidana, Saurabh P Nagar, Sabyasachi Ghosh, et al.Lung Cancer (Amsterdam, Netherlands)|March 13, 2026
EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world studySteven H Lin, Doreen A Kahangire, Saurabh P Nagar, et al.Clinical Epidemiology|June 2, 2026
Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple MyelomaDoris K Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz, et al.Current Medical Research and Opinion|April 30, 2026
Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptomsDoris K Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz, et al.Scientific Reports|September 14, 2021
Emergence and expansion of highly infectious spike protein D614G mutant SARS-CoV-2 in central IndiaShashi Sharma, Paban Kumar Dash, Sushil Kumar Sharma, et al.Pageof 7